M. Mason

1.1k total citations
18 papers, 777 citations indexed

About

M. Mason is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, M. Mason has authored 18 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 4 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in M. Mason's work include Prostate Cancer Treatment and Research (4 papers), Testicular diseases and treatments (3 papers) and Wnt/β-catenin signaling in development and cancer (3 papers). M. Mason is often cited by papers focused on Prostate Cancer Treatment and Research (4 papers), Testicular diseases and treatments (3 papers) and Wnt/β-catenin signaling in development and cancer (3 papers). M. Mason collaborates with scholars based in United Kingdom, United States and France. M. Mason's co-authors include G. Davies, Wen G. Jiang, David P. Dearnaley, Alissa K. Robbins, S.J. Harland, Florence I. Raynaud, Anne O’Donnell, Mitch Dowsett, Michael Jarman and Ian Judson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

M. Mason

18 papers receiving 756 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Mason United Kingdom 9 339 229 184 128 103 18 777
Lawrence R. Ragard United States 13 360 1.1× 253 1.1× 168 0.9× 59 0.5× 87 0.8× 28 1.1k
Gordon Moody United States 11 209 0.6× 303 1.3× 281 1.5× 70 0.5× 156 1.5× 24 836
Connie G. Chiu Canada 14 103 0.3× 304 1.3× 203 1.1× 140 1.1× 53 0.5× 19 702
Maria Alice Franzoi France 16 332 1.0× 568 2.5× 155 0.8× 44 0.3× 68 0.7× 51 868
Gaku Arai Japan 18 247 0.7× 253 1.1× 255 1.4× 55 0.4× 57 0.6× 73 912
Karol Axcrona Norway 22 654 1.9× 245 1.1× 248 1.3× 62 0.5× 84 0.8× 63 1.2k
Fortunato Bianconi Italy 13 289 0.9× 331 1.4× 280 1.5× 42 0.3× 35 0.3× 56 723
Fernando Franco Spain 14 211 0.6× 305 1.3× 215 1.2× 52 0.4× 39 0.4× 44 803
Lesley Lomo United States 15 82 0.2× 232 1.0× 206 1.1× 91 0.7× 69 0.7× 27 707
Brandon S. Sheffield Canada 20 625 1.8× 335 1.5× 167 0.9× 58 0.5× 46 0.4× 60 1.1k

Countries citing papers authored by M. Mason

Since Specialization
Citations

This map shows the geographic impact of M. Mason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Mason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Mason more than expected).

Fields of papers citing papers by M. Mason

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Mason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Mason. The network helps show where M. Mason may publish in the future.

Co-authorship network of co-authors of M. Mason

This figure shows the co-authorship network connecting the top 25 collaborators of M. Mason. A scholar is included among the top collaborators of M. Mason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Mason. M. Mason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
MacLennan, Sara, M. Mason, Karin Plass, et al.. (2020). EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel consensus statements for active surveillance for localised prostate cancer from an international collaborative study (DETECTIVE study). European Urology Open Science. 19. e1814–e1815. 3 indexed citations
2.
3.
Gambling, Tina, et al.. (2018). The volume of liver irradiated during modern free-breathing breast radiotherapy: Implications for theory and practice. Radiography. 25(2). 103–107. 1 indexed citations
4.
Vale, Claire L., David J. Fisher, James R. Carpenter, et al.. (2017). What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis. Annals of Oncology. 28. v620–v620. 5 indexed citations
5.
James, Nicholas D., Matthew R. Sydes, M. Mason, et al.. (2011). Celecoxib Plus Hormone Therapy Vs Hormone Therapy Alone for Hormone-sensitive Prostate Cancer: First Results From the STAMPEDE Randomised Controlled Trial (MRC PR08). European Journal of Cancer. 47. 11–11. 8 indexed citations
6.
Heidenreich, Axel, M. Bolla, Steven Joniau, et al.. (2011). Guía de la EAU sobre el cáncer de próstata: Parte I: cribado, diagnóstico y tratamiento del cáncer clínicamente localizado. Actas Urológicas Españolas. 35(9). 501–514. 22 indexed citations
7.
Martin, Tracey A., Gregory Harrison, M. Mason, & Wen G. Jiang. (2009). The Hepatitis A Virus Cellular Receptor, HAVcR-1, Reduces the Integrity of Human Endothelial Tight Junctions.. Cancer Research. 69(24_Supplement). 2158–2158. 1 indexed citations
8.
9.
Morris‐Stiff, Gareth, Andrew Steel, Philip Savage, et al.. (2004). Transmission of Donor Melanoma to Multiple Organ Transplant Recipients. American Journal of Transplantation. 4(3). 444–446. 58 indexed citations
10.
O’Donnell, Anne, Ian Judson, Mitch Dowsett, et al.. (2004). Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancer. 90(12). 2317–2325. 300 indexed citations
11.
Oliver, R.T.D., M. Mason, Hélène Massé, et al.. (2004). A randomised comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982. Journal of Clinical Oncology. 22(14_suppl). 4517–4517. 6 indexed citations
12.
Bisson, Jonathan I., Helen Chubb, Samantha Bennett, et al.. (2002). The prevalence and predictors of psychological distress in patients with early localized prostate cancer. British Journal of Urology. 90(1). 56–61. 117 indexed citations
13.
Adams, Malcolm, Leszek K. Borysiewicz, Alison Fiander, et al.. (2001). Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine. 19(17-19). 2549–2556. 93 indexed citations
14.
Davies, G., et al.. (2001). The HGF/SF-Induced Phosphorylation of Paxillin, Matrix Adhesion, and Invasion of Prostate Cancer Cells Were Suppressed by NK4, an HGF/SF Variant. Biochemical and Biophysical Research Communications. 285(5). 1330–1337. 43 indexed citations
15.
Davies, G., Wen G. Jiang, & M. Mason. (2001). HGF/SF modifies the interaction between its receptor c-Met, and the E-cadherin/catenin complex in prostate cancer cells. International Journal of Molecular Medicine. 7(4). 385–8. 27 indexed citations
16.
Davies, G., Wei Jiang, & M. Mason. (2001). The interaction between β-catenin, GSK3β and APC after motogen induced cell-cell dissociation, and their involvement in signal transduction pathways in prostate cancer. International Journal of Oncology. 18(4). 843–7. 17 indexed citations
17.
Davies, G., Wen G. Jiang, & M. Mason. (2000). CELL-CELL ADHESION MOLECULES AND SIGNALING INTERMEDIATES AND THEIR ROLE IN THE INVASIVE POTENTIAL OF PROSTATE CANCER CELLS. The Journal of Urology. 163(3). 985–992. 63 indexed citations
18.
Fish, R.G., et al.. (1994). Platinum Accumulation in Adult Cancer Patients Receiving Cisplatin. Clinical Drug Investigation. 7(4). 175–182. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lawrence R. Ragard Breakdown of academic impact, for papers by Gordon Moody Breakdown of academic impact, for papers by Connie G. Chiu Breakdown of academic impact, for papers by Maria Alice Franzoi Breakdown of academic impact, for papers by Gaku Arai Breakdown of academic impact, for papers by Karol Axcrona Breakdown of academic impact, for papers by Fortunato Bianconi Breakdown of academic impact, for papers by Fernando Franco Breakdown of academic impact, for papers by Lesley Lomo Breakdown of academic impact, for papers by Brandon S. Sheffield
Rankless by CCL
2026